Inhibrx's ozekibart posts 63% tumour response in Ewing sarcoma, opening a second FDA conversation
Early-stage data on the DR5 agonist with chemotherapy could widen the drug's potential commercial footprint beyond chondrosarcoma, though no filing plan has been disclosed.
Inhibrx Biosciences has given investors and clinicians a fresh look at how ozekibart performs in a second rare bone and soft-tissue cancer, and said it will take the findings to US regulators. The drug is already the subject of an accepted biologics licence application in conventional chondrosarcoma, so any move into Ewing sarcoma would add to a pipeline that currently rests heavily on one asset.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Inhibrx Biosciences, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.